• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Define Ventures Report Reveals Pharma Accelerates AI Investment for Enterprise-Scale Deployment

by Fred Pennic 07/17/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Define Ventures Report Reveals Pharma Accelerates AI Investment for Enterprise-Scale Deployment

What You Should Know: 

– Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today released a report revealing how Big Pharma is accelerating investment in AI to counter rising cost pressure, regulatory shifts, and growing competitive urgency. 

– The report is based on in-depth surveys and interviews with over 40 executives, including leaders from 16 of the top 20 pharma companies and major players like Amazon Web Services, NVIDIA, Oracle Life Sciences, Tempus AI, and Datavant, the report uncovers a decisive shift towards enterprise-scale AI deployment.

From Pilots to Enterprise-Scale: Pharma’s AI Strategy Matures & Accelerates

Bringing a new therapeutic to market is a lengthy and expensive process, with timelines and costs more than doubling over the past two decades (10–15 years and $2.6 billion, respectively). Against this backdrop, combined with cost-cutting and pricing pressure from the Inflation Reduction Act, pharma C-suite leaders increasingly view AI as a strategic necessity.

This urgency is translating into meaningful action and investment:

  • Immediate Priority: 70% of pharma leaders now consider AI an immediate priority, a number that rises to 85% among the top 20 pharma companies.
  • Increased Investment: Despite overall budget contractions, 85% of executives are increasing their AI investments (40% significantly, 45% somewhat), directing spend toward improving productivity, accelerating drug development, and protecting margins.
  • Key Priorities: 100% of respondents cite reducing administrative burden and improving workforce efficiency as AI success metrics, with R&D efficiency (80%) and revenue acceleration (75%) closely following. AI is seen as both an efficiency tool and an engine for scientific innovation.

The Build-vs-Buy Mentality Is Breaking Open

Historically, pharma companies favored building AI solutions in-house, especially for data and application layers, viewing proprietary data and scientific workflows as core strategic assets. However, this mindset is shifting. While 30% of pharma leaders still plan to primarily build in-house, 40% expect to split efforts between internal development and external partnerships, and 30% are prioritizing external-first strategies.

Despite growing openness, satisfaction with external vendors has been mixed: only 35% reported a somewhat positive experience, 40% neutral, and 5% somewhat negative, indicating high expectations for performance, seamless integration, and early ROI.

Big Tech Becomes Embedded in Pharma’s AI Stack

The report highlights the growing role of Big Tech and consulting firms as deeply embedded strategic partners in pharma’s AI transformation. Cloud providers, in particular, are moving up the stack, offering life science-specific solutions, including infrastructure, domain-tuned models, and co-development opportunities. 

Current AI Investment Focus: Low-Risk, High-Impact Efficiency Gains

Pharma companies are prioritizing AI investments in areas with low risk and immediate returns, with a clear emphasis on improving operational efficiency.

  • Medical Writing: 94% of respondents identified medical writing as a top AI priority for the next year, reflecting strong appetite for automation in high-volume areas with minimal regulatory or reputational risk.
  • Therapeutic Discovery: 80% of leaders are focused on reducing the cost of therapeutic discovery, streamlining tasks like literature reviews, hypothesis generation, and lab automation, and building infrastructure for complex multimodal data.

Pharma Outpacing Healthcare Peers in Operational Readiness

Pharma organizations are notably ahead of payers and providers in operational readiness for AI:

  • Governance: 80% of pharma companies have formal AI governance committees, compared to 73% of payers and providers, indicating strong institutional alignment across data, technology, and business leadership.
  • Funding Models: Pharma’s funding models demonstrate a shift from fragmented, department-led efforts to more centralized, enterprise-wide strategies. Only 20% of AI budget is allocated by innovation teams in pharma companies, compared to 60% for payers and providers, reflecting pharma’s readiness to scale AI.

“Pharma’s AI future will be defined in the next 12 to 24 months,” said Lynne Chou O’Keefe, Define Ventures founder and managing partner. “What we’re seeing is a decisive acceleration to enterprise execution — with leaders embedding AI into core workflows to drive speed, efficiency, and real ROI. But internal teams can’t do it alone. This moment is a generational opportunity for startups that are ready to scale, integrate seamlessly, and speak pharma’s language.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low, But AI Dominates and $1B+ IPOs Emerge

Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low

Digital Health Faces Q2’25 Pullback: Funding Falls to 5-Year Low

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |